Tyrosine + metformin

The entry "Tyrosine + metformin" does not represent a recognized biological target, such as a protein, receptor, or enzyme. It appears to be a combination of tyrosine, a non-essential amino acid, and metformin, a biguanide medication used for the treatment of type 2 diabetes (PubChem). Metformin's primary mechanism involves the activation of AMP-activated protein kinase (AMPK) and the inhibition of mitochondrial complex I to reduce hepatic glucose production (StatPearls). Tyrosine serves as a precursor for catecholamines like dopamine and norepinephrine and is essential for protein synthesis (NIH). There is no recognized therapeutic target or molecular entity that bears this combined name in pharmacological databases like DrugBank or UniProt. Consequently, this entry is classified as incorrect for the purposes of target identification. While metformin may influence tyrosine phosphorylation in signaling pathways, "Tyrosine + metformin" is not a valid nomenclature for a single target.

Not applicable as this is not a valid therapeutic target.